Status:
WITHDRAWN
Safety and Efficacy of Apixaban in Severe Renal Impairment
Lead Sponsor:
Albert Einstein College of Medicine
Conditions:
Renal Disease, End Stage
Anticoagulant-induced Bleeding
Eligibility:
All Genders
Brief Summary
Despite emergence of new anticoagulants over the last few years, patients with advanced chronic kidney disease still have limited options and are usually managed with warfarin after venous thromboembo...
Detailed Description
This is a retrospective cohort study. The investigators will use Clinical Looking Glass (CLG) to identify all adult patients with creatinine clearance \< 15 ml/min who were treated with apixaban or wa...
Eligibility Criteria
Inclusion
- Patients with creatinine clearance \<15 mL/min who are on anticoagulation with apixaban or warfarin.
Exclusion
- Patients without end stage renal disease who are not on anticoagulation with apixaban or warfarin.
Key Trial Info
Start Date :
May 10 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 24 2022
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03399305
Start Date
May 10 2017
End Date
August 24 2022
Last Update
August 26 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Montefiore Medical Center
The Bronx, New York, United States, 10467